Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543638 | PMC |
| http://dx.doi.org/10.1093/rheumatology/keaa581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics of COVID-19-associated multisystemic inflammatory syndrome in children treated in a Peruvian hospital, 2020-2022.
Rev Peru Med Exp Salud Publica
October 2024
Instituto Nacional de Salud del Niño-Breña, Lima, Perú.
Article Synopsis
- The study focuses on the variation of COVID-19-associated multisystem inflammatory syndrome (MIS-C) in Peru during the first three years of the pandemic, highlighting a decrease in cases over time.
- During the second wave, MIS-C was more prevalent, exhibiting symptoms similar to Kawasaki disease, with a significant portion of patients experiencing gastrointestinal and mucocutaneous issues.
- The findings suggest that while MIS-C cases decreased mainly due to vaccination efforts, healthcare providers need to remain vigilant in diagnosing MIS-C in unvaccinated children weeks after peak COVID-19 infection periods.
A New Case of Paediatric Systemic Lupus Erythematosus with Onset after SARS-CoV-2 and Epstein-Barr Infection-A Case Report and Literature Review.
Curr Issues Mol Biol
August 2024
Faculty of Medicine and Pharmacy, University "Dunarea de Jos" of Galati, 800008 Galati, Romania.
Article Synopsis
- * New autoimmune disorders, including multisystemic inflammatory syndrome in children (MIS-C) and systemic lupus erythematosus (SLE), have been reported after COVID-19.
- * The article discusses a pediatric case of SLE that developed three and a half months after COVID-19, suggesting a potential link between SARS-CoV-2 and Epstein-Barr in triggering this condition.
Both C-anti-neutrophil cytoplasmic antibody (ANCA) and P-ANCA vasculitis were reported to be associated with COVID-19 infection. The ideal management of COVID-19-associated ANCA vasculitis is unclear, as the experiences were limited to case reports. We presented a case of COVID-19-associated C-ANCA vasculitis, successfully treated with steroids and rituximab therapy without any significant adverse reactions.
View Article and Find Full Text PDFRelapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study.
Rheumatology (Oxford)
August 2024
Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens "Hippokration", Athens, Greece.
Objectives: There are limited real-life data regarding the efficacy and safety of rituximab (RTX) as a remission-maintenance agent in microscopic-polyangiitis (ΜPA) and granulomatosis-with-polyangiitis (GPA). We aimed to estimate the incidence and risk factors for relapses, as well serious-adverse-events (SAEs) in MPA/GPA patients during RTX-maintenance.
Methods: Retrospective cohort of newly-diagnosed/relapsing GPA/MPA patients who received RTX-maintenance (≥1 RTX-cycle, ≥6 months follow-up) following complete-remission (Birmingham-Vasculitis-Activity-Score-version-3 = 0 plus prednisolone ≤7.
Clinical characteristics and outcomes of COVID-19-associated encephalopathy in children.
J Neurovirol
April 2024
Department of Radiology, Hunan Children's Hospital, No. 86 Ziyuan Road, 410007, Changsha, Hunan, China.
Apart from the typical respiratory symptoms, coronavirus disease 2019 (COVID-19) also affects the central nervous system, leading to central disorders such as encephalopathy and encephalitis. However, knowledge of pediatric COVID-19-associated encephalopathy is limited, particularly regarding specific subtypes of encephalopathy. This study aimed to assess the features of COVID-19-associated encephalopathy/encephalitis in children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!